Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model

BACKGROUND: Antitumor therapies targeting programmed cell death-1 (PD-1) or its ligand-1 (PD-L1) are used in various cancers. However, in glioblastoma (GBM), the expression of PD-L1 varies between patients, and the relationship between this variation and the efficacy of anti-PD-1 antibody therapy re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Izumi, Nakajima, Kohei, Shono, Kenji, Mizobuchi, Yoshifumi, Fujihara, Toshitaka, Shikata, Eiji, Yamaguchi, Tadashi, Kitazato, Keiko, Sampetrean, Oltea, Saya, Hideyuki, Takagi, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212915/
https://www.ncbi.nlm.nih.gov/pubmed/32642723
http://dx.doi.org/10.1093/noajnl/vdz058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212915/
https://www.ncbi.nlm.nih.gov/pubmed/32642723
http://dx.doi.org/10.1093/noajnl/vdz058

Ejemplares similares